KRAS and colorectal cancer: FOCUS4-D has shown no evidence of efficacy of single-agent EGFR, HER2, and HER3 inhibition with AZD8931 in patients with advanced colorectal cancer whose tumours are wild-type for BRAF, PIK3CA, KRAS, and NRAS after first-line induction therapy.